Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical College, Wenzhou 325027, China.
Gynecol Oncol. 2012 Jul;126(1):140-6. doi: 10.1016/j.ygyno.2012.04.005. Epub 2012 Apr 6.
Abnormal expression of Annexin A2 and S100A proteins has been reported to induce sensitivity/resistance to chemotherapy in a variety of cancers. The aim of this study was to evaluate the significance of Annexin A2 and S100A protein expression to predict response to neoadjuvant chemotherapy and prognostic significance of these protein expressions in bulky stage IB-IIA cervical cancer patients.
Paired tumor samples (pre- and post-chemotherapy) were obtained from 68 patients who were treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy at our hospital from 2006 to 2011. The expression of Annexin A2 and S100A proteins was analyzed by immunohistochemistry.
Thirty-six patients were identified as chemotherapy-response and 32 were non-response. (a). Protein expression in tumor cells: (1). Exposure of tumor cells to chemotherapy results in a change of Annexin A2 and S100A expression (P<0.05). (2). Annexin A2, S100A8 and S100A9 protein expression correlates with tumor response to chemotherapy (P<0.05). (b). Protein expression in stromal cells: (1). Expression of Annexin A2, S100A8 and S100A9 was increased, but S100A2 and S100A4 was decreased after exposure to chemotherapy (P<0.05). (2). Only S100A4 expression was associated with response to chemotherapy (P<0.05). Multivariate analysis revealed that tumor size (P=0.022), differentiation (P=0.000), Annexin A2 expression in stromal cells (P=0.009), and S100A8 expression in tumor cells (P=0.008) were independent prognostic factors for progression-free survival of cervical cancer patients.
Expression of some of the measured proteins in tumor and stromal cells correlates with chemotherapy exposure, response to therapy, and progression-free survival.
已有研究报道 Annexin A2 和 S100A 蛋白的异常表达可诱导多种癌症对化疗的敏感性/耐药性。本研究旨在评估 Annexin A2 和 S100A 蛋白表达对预测新辅助化疗反应的意义，以及这些蛋白在巨块型 IB-IIA 期宫颈癌患者中的表达对预后的影响。
对 2006 年至 2011 年在我院接受顺铂为基础的新辅助化疗和根治性子宫切除术的 68 例患者的配对肿瘤标本（化疗前和化疗后）进行了研究。采用免疫组织化学法分析 Annexin A2 和 S100A 蛋白的表达。
36 例患者被确定为化疗反应者，32 例为非反应者。（a）肿瘤细胞中蛋白的表达：（1）肿瘤细胞暴露于化疗后 Annexin A2 和 S100A 表达发生改变（P<0.05）。（2） Annexin A2、S100A8 和 S100A9 蛋白的表达与肿瘤对化疗的反应相关（P<0.05）。（b）基质细胞中蛋白的表达：（1）暴露于化疗后，Annexin A2、S100A8 和 S100A9 的表达增加，而 S100A2 和 S100A4 的表达减少（P<0.05）。（2）只有 S100A4 的表达与化疗反应相关（P<0.05）。多因素分析显示肿瘤大小（P=0.022）、分化（P=0.000）、基质细胞中 Annexin A2 的表达（P=0.009）和肿瘤细胞中 S100A8 的表达（P=0.008）是宫颈癌患者无进展生存的独立预后因素。
一些测量的肿瘤和基质细胞中的蛋白的表达与化疗暴露、对治疗的反应和无进展生存相关。
